Fisher Asset Management LLC lessened its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 6.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 893,700 shares of the biotechnology company’s stock after selling 63,991 shares during the period. Fisher Asset Management LLC owned about 0.63% of Arrowhead Pharmaceuticals worth $58,493,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in ARWR. Carolina Wealth Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 154 shares during the period. Optiver Holding B.V. raised its holdings in Arrowhead Pharmaceuticals by 83.8% in the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 186 shares in the last quarter. Versant Capital Management Inc lifted its position in shares of Arrowhead Pharmaceuticals by 285.1% in the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 248 shares during the period. QRG Capital Management Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 7.1% in the 2nd quarter. QRG Capital Management Inc. now owns 4,810 shares of the biotechnology company’s stock worth $392,000 after acquiring an additional 317 shares during the period. Finally, Pine Valley Investments Ltd Liability Co lifted its position in shares of Arrowhead Pharmaceuticals by 1.8% in the 1st quarter. Pine Valley Investments Ltd Liability Co now owns 18,814 shares of the biotechnology company’s stock worth $1,180,000 after acquiring an additional 335 shares during the period. Institutional investors own 62.61% of the company’s stock.
Insider Activity at Arrowhead Pharmaceuticals
In other Arrowhead Pharmaceuticals news, Director Michael S. Perry sold 11,600 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the transaction, the director directly owned 111,459 shares in the company, valued at $9,730,370.70. This represents a 9.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total value of $173,920.00. Following the transaction, the director owned 31,600 shares of the company’s stock, valued at $2,747,936. This represents a 5.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.60% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
ARWR has been the topic of several recent research reports. Morgan Stanley lifted their price objective on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Wall Street Zen lowered Arrowhead Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Saturday. The Goldman Sachs Group started coverage on Arrowhead Pharmaceuticals in a research report on Thursday, September 24th. They issued a “neutral” rating and a $74.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $120.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Friday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $98.93.
Get Our Latest Research Report on Arrowhead Pharmaceuticals
Trending Headlines about Arrowhead Pharmaceuticals
Here are a few of the latest headlines about ARWR:
- Neutral Sentiment: Stifel Nicolaus kept its “buy” rating but lowered its price target to $96 from $104, reflecting a more cautious valuation while retaining a bullish view. Stifel Nicolaus rating
- Negative Sentiment: For the quarter, Arrowhead reported a $3.00-per-share loss, worse than analysts’ expected $1.52 loss. Revenue of $37.79 million also fell short of the $61.18 million consensus and declined 45.6% year over year, weighing on sentiment around the company’s results. Quarterly earnings report
- Negative Sentiment: Arrowhead reported a full-year fiscal 2026 loss of $5.11 per share. An earnings analysis also highlights the challenge of making costly R&D pay off as market sentiment toward RNA interference (RNAi) turns more skeptical. Full-year earnings results Earnings analysis
Arrowhead Pharmaceuticals Price Performance
Shares of ARWR opened at $47.78 on Monday. The stock has a market cap of $6.73 billion, a price-to-earnings ratio of -9.35 and a beta of 1.34. The company has a quick ratio of 4.11, a current ratio of 4.14 and a debt-to-equity ratio of 16.61. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $37.06 and a 12 month high of $95.49. The company has a 50-day moving average price of $63.32 and a two-hundred day moving average price of $71.00.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.
Featured Stories
- Five stocks we like better than Arrowhead Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report).
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
